Holen Sie sich die Stockscreener-App
445.20
0.88%
3.90
Vorhandelsmarkt:
443.28
-1.92
-0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$441.30
Offen:
$440.45
24-Stunden-Volumen:
1.11M
Relative Volume:
0.68
Marktkapitalisierung:
$115.95B
Einnahmen:
$11.10B
Nettoeinkommen (Verlust:
$-988.90M
KGV:
-113.57
EPS:
-3.92
Netto-Cashflow:
$-1.26B
1W Leistung:
+0.37%
1M Leistung:
+0.71%
6M Leistung:
+10.55%
1J Leistung:
-5.02%
1-Tages-Spanne:
$439.23
$446.45
1-Wochen-Bereich:
$439.23
$451.88
52-Wochen-Spanne:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
10 Biotech Stocks Screaming a Buy - Insider Monkey
Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives - Insider Monkey
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Price Target Slightly Reduced by R - GuruFocus
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts - Nasdaq
Vertex Pharmaceuticals price target lowered to $420 from $423 at RBC Capital - TipRanks
Vertex Pharmaceuticals (VRTX) Price Target Lowered Amid Concerns - GuruFocus
Vertex Pharmaceuticals (VRTX) Price Target Lowered Amid Concerns | VRTX Stock News - GuruFocus
RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating - MarketScreener
Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire Inc.
Aries Wealth Management Buys New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Everhart Financial Group Inc. Buys 553 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CCM Investment Advisers LLC Acquires 5,351 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Opinicus Capital Inc. Invests $397,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Ferguson Wellman Capital Management Inc. Takes $391,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by RMR Wealth Builders - MarketBeat
Integrated Advisors Network LLC Has $1.05 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Optas LLC Has $864,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Brighton Jones LLC Purchases 1,994 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Foster Victor Wealth Advisors LLC Sells 1,664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Massachusetts Wealth Management Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Yousif Capital Management LLC Sells 664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simplicity Wealth LLC Has $630,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Redhawk Wealth Advisors Inc. Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com
Compagnie Lombard Odier SCmA Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simon Quick Advisors LLC Has $1.42 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
SG Americas Securities LLC Purchases 17,502 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Greenwood Capital Associates LLC Sells 6,572 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Stanley Laman Group Ltd. Buys New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
UMB Bank n.a. Sells 1,666 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Handelsbanken Fonder AB Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
Boston drug company laying off 125 employees in R.I. - Boston.com
Boston probes misconduct claims against city official - Axios
Portside Wealth Group LLC Has $1.43 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Presents New Data on the Benefits of ALYFTREK - Insider Monkey
Vertex Pharmaceuticals lays off 125 workers in RI - WPRI.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Lifted by Wedmont Private Capital - MarketBeat
Boston drugmaker Vertex slashes Providence workforce, shrinks real estate following trial failure - The Business Journals
SeaCrest Wealth Management LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex to lay off 125 employees in R.I., consolidate offices - The Boston Globe
Vertex lays off 125 staffers, slims Rhode Island campus after ditching failed diabetes cell-device combo - Fierce Biotech
Vertex lays off 125 staffers after halting work on diabetes 'cells plus device' therapy - FirstWord Pharma
After axing diabetes asset, Vertex lays off 140 staff - PharmaLive
After Axing Diabetes Asset, Vertex Lays Off 140 Staff - BioSpace
Five things: The Newbury GM, Zoominfo cuts, Vertex, Boston Scientific and casino night - The Business Journals
How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks? - MSN
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):